



Mauna Kea Technologies Reports 155% First Quarter Sales Growth

PARIS (April 18, 2012) – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), the leader in the endomicroscopy market, today announced its sales for the first quarter of 2012.

<i>In €k</i> <i>IFRS</i>	Q1 2012 <i>31 March 2012</i>	Q1 2011 <i>31 March 2011</i>	Growth %
Sales	1,611	631	+155%

Mauna Kea Technologies reported a 155% growth in sales for the first fiscal quarter, ended March 31, 2012 which drove the company’s overall sales for the period to €1.61 million, from €631,000 in the same period last year.

Clinical sales (sales to hospitals) more than doubled, rising 105% to €1.24 million. This segment now accounts for 77% of the company’s global sales. Sales to preclinical research laboratories were €367,500 compared to €24,300 last year.

Equipment sales – or sales of Cellvizio systems – rose 228% to €1.20 million. The sale of consumables (miniprobes) also showed a significant increase of 160% to €337,000, while the sales of services fell by 46% to €72,000.

Sales from North America now account for 57% of the company’s global sales, while the Europe Middle East and Africa (EMEA) and Asia Pacific regions account for 20% and 23% of sales, respectively.

"We are pleased with the sharp increase of product sales across the board, especially during a period which has been slower historically," Sacha Loiseau, Founder and CEO of Mauna Kea Technologies, said. *"This very strong growth reflects our ongoing efforts to build highly effective marketing and sales activities worldwide."*

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company and leader in the endomicroscopy market. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio’s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.

For more information about Mauna Kea Technologies, go to www.maunakeatech.com



Next press release: 2012 first-half sales: July 11th, 2012 (after closing bell)

United States

Lazar Partners Ltd.

Erich Sandoval

Tel: +1 917 497 2867

esandoval@lazarpartners.com

France et Europe

ALIZE RP

Caroline Carmagnol

Tel: +33 (0)1 42 68 86 43 / +33 (0)6 64 18 99 59

caroline@alizerp.com

Anne –Sophie Cosquéric

Tel: +33 (0)1 42 68 86 41

anne-sophie@alizerp.com

Mauna Kea Technologies

Eric Cohen

Vice-President Finance

Tel: +33 (0) 1 70 08 09 70

investor-vpf@maunakeatech.com

NewCap.

Investor Relations and Financial Communication

Pierre Laurent / Florent Alba

Tel: +33(0)1 44 71 94 94

maunakea@newcap.fr

MKEA
LISTED
NYSE
EURONEXT